ADMA - NASDAQ
ADMA Biologics, Inc.
$7.93
+2.3%ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
At a Glance
Live SnapshotADMA Biologics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
ADMA Biologics, Inc. Cash Flow Statement
ADMA • NASDAQ
| ADMA Biologics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||||||
146.9M | 197.7M | -28.2M | -65.9M | -71.6M | -75.7M | -48.3M | -65.7M | -43.8M | -19.5M | -18M | -16.8M | -15.5M | -7.3M | -26.5K | -20.5K | -20M | -24.9M | -29.7M | |
8.1M | 8M | 8.3M | 7.1M | 5.5M | 3.9M | 3.3M | 3.4M | 2.7M | 469.6K | 469.8K | 247.9K | 210.6K | 182.1K | 0.0 | 220K | 0.0 | 0.0 | 0.0 | |
11M | -84.3M | 0.0 | 0.0 | 220.8K | -910.1K | 0.0 | 122.2K | 1.9M | 0.0 | 651.2K | 74.4K | -43.3K | 18.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
20M | 13.6M | 6.2M | 5.2M | 3.5M | 2.9M | 2.7M | 0.0 | 1.6M | 1.3M | 1.7M | 1.2M | 888.3K | 626.8K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.9M | 2.2M | 32.6M | 12.4M | 1.8M | 1.6M | -320.3K | 961.3K | 638.7K | 534.1K | 390.5K | 359.7K | 146.9K | 7.5K | 0.0 | -220K | -14.9M | 23.8M | 1.5M | |
(0.0) | (9.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-139.6M | -18.5M | -10.1M | -18.3M | -51.7M | -33.8M | -33.5M | -3.7M | -282.2K | -1M | -671.1K | 177.9K | 3.4M | -437.2K | -2.5K | 850.0 | 10.5M | -17.9M | 4.6M | |
50.4M | 118.7M | 8.8M | -59.5M | -112.4M | -102M | -76.2M | -62.7M | -37.3M | -18.3M | -15.4M | -14.7M | -10.9M | -6.9M | -29K | -19.7K | -24.5M | -19M | -23.6M | |
INVESTING ACTIVITIES | |||||||||||||||||||
-22.6M | -8.2M | -4.8M | -13.9M | -13.5M | -12.7M | -3.8M | -2.1M | -2.7M | -73.4K | -26.1K | -2.3M | -196.6K | -118.9K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(1M) | (0.0) | (0.0) | (0.0) | (0.0) | (2K) | (0.0) | (0.0) | (12.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -12.5M | -15.7M | -1.7M | -1.7M | -2.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.4M | 16.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-316K | -349K | -210K | 0.0 | 0.0 | 2K | 0.0 | 0.0 | 12.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-21.9M | -8.6M | -5M | -13.9M | -13.5M | -12.7M | -3.8M | -2.1M | (15.2M) | (904.6K) | -1.7M | -4M | -3.1M | -118.9K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||||||||
-29M | 7.5M | -1.4M | 64.6M | 121.1M | 131.2M | 48.4M | 42.9M | 39.2M | 12.9M | 10.3M | 0.0 | 27M | 17.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-3.2M | -60M | -23.6M | 51.7M | -34K | 13.5M | 42.5M | -36.3K | 25M | 4M | 685.4K | 9.8M | 988.4K | 3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-31.9M | (0.0) | -1.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -150K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-11.9M | -5.8M | -14M | -7.5M | -62K | -816.6K | -10.9M | 13K | -3.4M | -47.1K | 9.7M | -42.1K | -386.5K | -25K | 1.3M | 23K | 30.5M | 7M | 12.5K | |
-44M | -58.3M | -39M | 108.9M | 121M | 143.9M | 80M | 42.9M | 60.8M | 16.8M | 10.4M | 9.8M | 27.6M | 19.5M | 25.5K | 23K | 30.5M | 7M | 12.5M | |
CASH FLOW SUMMARY | |||||||||||||||||||
-15.5M | 51.8M | -35.2M | 35.4M | -4.8M | 29.2M | -2.7K | -21.9M | 38.7M | -526.1K | -6.8M | -9M | 13.6M | 12.4M | -3.5K | 3.3K | 6M | -12M | -11.1M | |
103.1M | 51.4M | 86.5M | 51.1M | 55.9M | 26.8M | 26.8M | 48.6M | 9.9M | 10.4M | 17.2M | 26.1M | 12.5M | 87.8K | 12K | 8.7K | 2.6M | 14.7M | 25.8M | |
87.6M | 103.1M | 51.4M | 86.5M | 51.1M | 55.9M | 26.8M | 26.8M | 48.6M | 9.9M | 10.4M | 17.2M | 26.1M | 12.5M | 8.5K | 12K | 8.7M | 2.6M | 14.7M | |
27.8M | 110.1M | 3.8M | -73.4M | -125.9M | -114.7M | -80M | -64.8M | -39.9M | -18.3M | -15.4M | -17M | -11.1M | -7M | -29K | -19.7K | -24.5M | -19M | -23.6M |
SEC Filings
ADMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 15, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your ADMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.